Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Extension Study in CLL/SLL (PCYC-1116-CA)
CTR20132531Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Janssen Pharmaceutical. Started Sep 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20132531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132531.